Over the last few years, the number of research publications about the role of catecholamines (epinephrine, norepinephrine, and dopamine) in the development of liver diseases such as liver fibrosis, fatty liver diseases, or liver cancers is constantly increasing. However, the mechanisms involved in these effects are not well understood. In this review, we first recapitulate the way the liver is in contact with catecholamines and consider liver implications in their metabolism. A focus on the expression of the adrenergic and dopaminergic receptors by the liver cells is also discussed. Involvement of catecholamines in physiological (glucose metabolism, lipids metabolism, and liver regeneration) and pathophysiological (impact on drug-metabolizing enzymes expression, liver dysfunction during sepsis, fibrosis development, or liver fatty diseases and liver cancers) processes are then discussed. This review highlights the importance of understanding the mechanisms through which catecholamines influence liver functions in order to draw benefit from the adrenergic and dopaminergic antagonists currently marketed. Indeed, as these molecules are well-known drugs, their use as therapies or adjuvant treatments in several liver diseases could be facilitated.
Tumor cells display important plasticity potential, which contributes to intratumoral heterogeneity. Notably, tumor cells have the ability to retrodifferentiate toward immature states under the influence of their microenvironment. Importantly, this phenotypical conversion is paralleled by a metabolic rewiring, and according to the metabostemness theory, metabolic reprogramming represents the first step of epithelial-to-mesenchymal transition (EMT) and acquisition of stemness features. Most cancer stem cells (CSC) adopt a glycolytic phenotype even though cells retain functional mitochondria. Such adaptation is suggested to reduce the production of reactive oxygen species (ROS), protecting CSC from detrimental effects of ROS. CSC may also rely on glutaminolysis or fatty acid metabolism to sustain their energy needs. Besides pro-inflammatory cytokines that are well-known to initiate the retrodifferentiation process, the release of catecholamines in the microenvironment of the tumor can modulate both EMT and metabolic changes in cancer cells through the activation of EMT transcription factors (ZEB1, Snail, or Slug (SNAI2)). Importantly, the acquisition of stem cell properties favors the resistance to standard care chemotherapies. Hence, a better understanding of this process could pave the way for the development of therapies targeting CSC metabolism, providing new strategies to eradicate the whole tumor mass in cancers with unmet needs.
Les catécholamines jouent un rôle dans des processus physiopathologiques hépatiques. Néanmoins, une forte activité du système nerveux sympathique, en sécrétant les catécholamines, peut contribuer à la progression tumorale de certains types de cancer. Il semblerait que le carcinome hépatocellulaire (CHC), un cancer primitif du foie, en fasse également partie. Ainsi, le but de cette étude est de déterminer les principaux mécanismes pouvant être responsables des effets des catécholamines en utilisant des hépatocytes-HepaRG tumoraux et des hépatocytes humains en culture primaire. Des techniques de biologie moléculaire et des analyses transcriptomiques ont été utilisées. Les hépatocytes-HepaRG expriment les récepteurs α1A- et β2-adrénergiques et métabolisent effectivement les catécholamines. Ces dernières stimulent dans notre modèle une réponse inflammatoire avec production d’interleukine 6, une prolifération cellulaire, une transition épithélio-mésenchymateuse de type II, un remodelage matriciel, une angiogenèse/hypoxie, une résistance à l’anoïkis et potentiellement une reprogrammation métabolique. La régulation de la sécrétion de la bile semble également altérée, avec la répression gènes clés et l’augmentation du nombre des canalicules biliaires. Cette étude souligne le rôle des catécholamines dans la progression des CHC via la stimulation de processus notamment retrouvés lors de la régénération hépatique ou les maladies chroniques du foie telles que la fibrose.